Be the first to like this
Bristol-Myers Squibb (NYSE: BMY) is one of the globe's top drugmakers and is a staple in dividend investors' portfolios.That's because big drug companies like Bristol-Myers, Johnson & Johnson (NYSE: JNJ) and Merck (NYSE: MRK) offer investors predictable, dividend-boosting revenue regardless of the economy's whims and whispers. But investors are correct to wonder if Bristol-Myers dividend can continue following the loss of patent protection on its top selling drug Plavix two years ago and in light of billions more in at-risk revenue tied to future patent expiration.
In the following slideshow you'll see whether I think Bristol's dividend is safe and gain insight into how Bristol matches up with industry peers.
Clipping is a handy way to collect important slides you want to go back to later.